Pfizer has found a leading experimental drug candidate against SARS-CoV-2 and is planning to test the drug in the coming months.
Pfizer’s R&D chief Mikael Dolsten says that early R&D has shown its candidate blocks the new virus, which causes COVID-19, from replicating, suggesting it could slow or stop the spread of the virus in patients with mild to moderate symptoms.